Suzanne Jacques-O'Hagan

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Nicholas D. Adams, K. Swinger, R. Prinjha, 2019, Cancer cell.

Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?

S. Kazmirski, J. Penzotti, H. Tecle, 2009, Bioorganic & medicinal chemistry letters.

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Nicholas D. Adams, K. Swinger, R. Prinjha, 2019, Cancer cell.